Amycretin
InvestigationalA novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
8 human studies
- Preclinical
- 33%
- Clinical
- 67%
Based on 12 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
ResearchDepth: two placebo-controlled phase 1/1b-2a Lancet RCTs (oral PMID:40550229, SC PMID:40550231), total human N <300, no SR yet. Mechanism: well-characterized dual GLP-1R + amylin-receptor agonism with mapped hypothalamic/area-postrema pathways and SC dose-response. Plausibility: full mechanism-to-weight-loss chain, coherent with incretin biology, strong same-class analogy (semaglutide, CagriSema). GlobalCoverage: single-sponsor, single US site, not yet independently replicated, advancing to phase 3. CommunityExperience: investigational, negligible real-world use outside trials. Effectiveness basis clinical: SC amycretin ~24% weight loss (placebo-subtracted ~23pp) far exceeds obesity MCID; confidence low (early small phase 1/2 data, one sponsor).
The proposed mechanisms of amycretin are based on Phase 1 clinical data and extensive preclinical validation of the dual GLP-1/amylin pathway approach.
How It Works (Simplified)
Amycretin is a single molecule designed to activate two appetite-control systems simultaneously:
Activates GLP-1 receptors in hypothalamus for appetite suppression and pancreas for glucose-dependent insulin release, like semaglutide.
Activates amylin receptors in brainstem (area postrema) providing a second, independent satiety signal through different neural circuits.
Amylin pathway restores responsiveness to leptin in obesity, a mechanism not achieved by GLP-1 agonists alone.
Engineered for oral delivery using absorption enhancer technology, enabling once-daily pill format versus weekly injections.
Key Research: Roth JD et al. (2008) demonstrated amylin restores leptin sensitivity in obesity. PMID:18458326
Important Limitations
- Peer-reviewed efficacy data are limited to early-phase trials (phase 1 oral and phase 1b/2a subcutaneous, both published in The Lancet in 2025); phase 3 outcome data are not yet available
- A large phase 3 program (AMAZE) and phase 2/3 type 2 diabetes trials are registered and underway, but their results have not yet been published
- Subcutaneous phase 1b/2a trial had a high participant withdrawal rate, which limits interpretation of the bodyweight findings
- Long-term safety beyond 36 weeks not established
- Head-to-head comparisons with semaglutide/tirzepatide are indirect only
- Molecular structure and sequence not publicly available
Based on GLP-1/amylin class effects: Initial appetite suppression and reduced food intake. GI side effects (nausea, reduced appetite) most common during this period. Weight loss begins, typically 2-4% in first month.
Oral phase 1 data: weight reduction observed over the 12-week multiple-ascending-dose period as dose escalation completes. GI tolerability typically improves after initial weeks.
Continued weight loss trajectory. In the subcutaneous phase 1b/2a trial, weight loss continued beyond week 12. Metabolic improvements (if diabetic) would be expected based on class effects.
Subcutaneous phase 1b/2a trial reported bodyweight reductions of up to ~24% vs placebo at week 36 (60 mg arm). Weight loss may begin plateauing at higher doses. Long-term tolerance and adherence not yet characterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (4 indicators)
Warning Signs (3 indicators)
Bad Signs (4 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Semaglutide
CautionBoth are GLP-1 receptor agonists. Combining would result in overlapping mechanisms with potential for additive GI side effects. Not intended for concurrent use.
Tirzepatide
CautionBoth target GLP-1 receptor with additional mechanisms. Concurrent use would provide overlapping GLP-1 activity. Not recommended for combination.
Liraglutide
CautionBoth are GLP-1 receptor agonists. Overlapping mechanisms would not provide additive benefit and may increase adverse event risk.
Cagrisema
AvoidCagriSema contains both GLP-1 and amylin agonist components. Amycretin duplicates this dual mechanism in a single molecule. Combination would be redundant and potentially unsafe.
Cagrilintide
AvoidAmycretin already incorporates amylin receptor agonism. Adding cagrilintide would duplicate the amylin pathway with no expected additional benefit.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Amycretin
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Ecnoglutide
XW003 · Sciwind GLP-1
A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
Liraglutide
Victoza · Saxenda · NN2211
The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.